WilmerHale Advises Underwriters in Follow-On Public Offering of Amylyx Pharmaceuticals

WilmerHale Advises Underwriters in Follow-On Public Offering of Amylyx Pharmaceuticals

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
WilmerHale represented the underwriters in the follow-on public offering of 7,697,812 shares of common stock of Amylyx Pharmaceuticals, Inc., a biopharmaceutical company founded with the goal of improving the quality and length of life for patients suffering from neurodegenerative diseases. The shares of common stock were issued at a public offering price of $32.00 per share. The gross proceeds to Amylyx were $246.3 million before deducting underwriting discounts, commissions, and offering expenses. The offering priced on October 6, 2022 and closed on October 11, 2022. The team consisted of Lisa Firenze, Jeffries Oliver-Li, Ryan Brewer, and Molly Nelson, with assistance from Stuart Falber, Bruce Manheim, Colleen Superko, and Heidi Treiber.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link. (The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel